BEGIN:VCALENDAR

VERSION:2.0

PRODID:-//wp-events-plugin.com//7.2.2.1//EN

TZID:Asia/Jerusalem

X-WR-TIMEZONE:Asia/Jerusalem
BEGIN:VEVENT

UID:704@biology.technion.ac.il

DTSTART;TZID=Asia/Jerusalem:20170509T133000

DTEND;TZID=Asia/Jerusalem:20170509T143000

DTSTAMP:20210802T125847Z

URL:https://biology.technion.ac.il/en/seminars/prof-jane-cullis-nyu-school
 -of-medicine-nyc-usa-2/

SUMMARY:Prof. Jane Cullis\, NYU School of Medicine\, NYC\, USA [No Categori
 es]
DESCRIPTION:Location:   \n Affiliation: \n Host:\n Title: Harnessing Macrop
 hage Macropinocytosis as a Therapeutic Strategy in Pancreatic Cancer\n\nAb
 stract: \nPancreatic cancer is a devastating disease that is largely refra
 ctory to currently available treatment strategies. Therapeutic resistance 
 is partially attributed to the dense stromal reaction of pancreatic ductal
  adenocarcinoma tumors that includes a pervasive infiltration of immunosup
 pressive (M2) macrophages. Nab-paclitaxel (trade name Abraxane) is a nanop
 article albumin-bound formulation of paclitaxel that\, in combination with
  gemcitabine\, is currently the first-line treatment for pancreatic cancer
 . We show that macrophages internalize high levels of nab-paclitaxel via m
 acropinocytosis. The macropinocytic uptake of nab-paclitaxel induces macro
 phage immunostimulatory (M1) activation in vitro and in an orthotopic mode
 l of pancreatic cancer. These data reveal an unanticipated role for nab-pa
 clitaxel in macrophage activation and rationalize the development of album
 in-coupled immunostimulatory agents to effectively target and re-polarize 
 macrophages in pancreatic cancer.\nHost: David Meiri 

END:VEVENT

BEGIN:VTIMEZONE

TZID:Asia/Jerusalem

X-LIC-LOCATION:Asia/Jerusalem

BEGIN:DAYLIGHT

DTSTART:20170324T030000

TZOFFSETFROM:+0200

TZOFFSETTO:+0300

TZNAME:IDT

END:DAYLIGHT

END:VTIMEZONE
END:VCALENDAR